Evaluation of the clinical impact of bone marrow cultures in current medical practice.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
11 06 2022
Historique:
received: 27 03 2022
accepted: 31 05 2022
entrez: 11 6 2022
pubmed: 12 6 2022
medline: 15 6 2022
Statut: epublish

Résumé

The clinical yield and benefit of performing bone marrow cultures for various clinical indications has been challenged and their clinical necessity remains debatable. We sought to assess the clinical yield and benefit of performing routine bone marrow cultures and determine whether various clinical, laboratory, and imaging parameters were predictive of a diagnostic bone marrow culture. This was a single center retrospective analysis of all patients who underwent a bone marrow study comprising bone marrow cultures from January 1, 2012, through March 1, 2018. Baseline clinical data were extracted from the institution's electronic medical records system. The analyzed cohort consisted of 139 patients with a median age of 46 years (range 4 months to 85 years). The most common indication for a bone marrow study was workup of a fever of unknown origin (105 patients, 76%) while investigation for infection in immunocompromised patients accounted for 22 cases (16%) and suspected tuberculosis was the reason for acquisition of bone marrow cultures in 6 patients (4%). Only 3 patients had positive bone marrow cultures, yielding in 2 patients a diagnosis of Mycobacterium avium and in one patient a microbiologically unclassifiable fungal infection. A univariate analysis revealed that mean age, hemoglobin level, platelet count, c-reactive protein levels, gender, indication for bone marrow study, yield of blood cultures, and contribution of imaging studies and bone marrow pathology results were not significantly different between patients with diagnostic and non-diagnostic bone marrow cultures. Mean white blood cell count was found to be significantly lower in patients with diagnostic bone marrow cultures (2.4 × 10

Identifiants

pubmed: 35690634
doi: 10.1038/s41598-022-14059-3
pii: 10.1038/s41598-022-14059-3
pmc: PMC9188585
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

9664

Informations de copyright

© 2022. The Author(s).

Références

Clin Microbiol Infect. 2004 Aug;10(8):734-7
pubmed: 15301676
Arch Intern Med. 2009 Nov 23;169(21):2018-23
pubmed: 19933965
J Clin Pathol. 1995 Aug;48(8):706-9
pubmed: 7560193
Am J Hematol. 2001 Jun;67(2):100-6
pubmed: 11343381
Medicine (Baltimore). 2014 Dec;93(27):e243
pubmed: 25501092
Mayo Clin Proc. 2012 Feb;87(2):136-42
pubmed: 22226833
Trop Doct. 1991 Oct;21(4):174-6
pubmed: 1746041
Am J Clin Pathol. 1998 Aug;110(2):150-3
pubmed: 9704612
Scand J Infect Dis. 1993;25(6):787-9
pubmed: 8052823
Indian J Hematol Blood Transfus. 2017 Mar;33(1):142-143
pubmed: 28194075
Int J Tuberc Lung Dis. 1999 Oct;3(10):908-12
pubmed: 10524589
Am J Clin Pathol. 1998 Dec;110(6):806-9
pubmed: 9844594
Am J Med. 1998 Feb;104(2):123-8
pubmed: 9528729
J Clin Microbiol. 1986 Aug;24(2):312-4
pubmed: 3745428

Auteurs

Gal Sharvit (G)

Division of Hematology, Chaim Sheba Medical Center, Faculty of Medicine, Tel Aviv University, Tel Hashomer, Derech Sheba 2, 52621, Ramat Gan, Israel.

Daniel Schwartz (D)

MetroHealth Medical Center, Case Western Reserve University, 2500 Metrohealth Dr, Cleveland, OH, 44109, USA.

Gabriel Heering (G)

Westchester Medical Center, 100 Woods Rd, Valhalla, NY, 10595, USA.

Alexander Shulman (A)

The Infectious Diseases Unit, Chaim Sheba Medical Center, Faculty of Medicine, Tel Aviv University, Tel Hashomer, Derech Sheba 2, 52621, Ramat Gan, Israel.

Abraham Avigdor (A)

Division of Hematology, Chaim Sheba Medical Center, Faculty of Medicine, Tel Aviv University, Tel Hashomer, Derech Sheba 2, 52621, Ramat Gan, Israel.

Galia Rahav (G)

The Infectious Diseases Unit, Chaim Sheba Medical Center, Faculty of Medicine, Tel Aviv University, Tel Hashomer, Derech Sheba 2, 52621, Ramat Gan, Israel.

Amos Toren (A)

Pediatric Hemato-Oncology Division, Chaim Sheba Medical Center, Faculty of Medicine, Tel Aviv University, Tel Hashomer, Derech Sheba 2, 52621, Ramat Gan, Israel.

Arnon Nagler (A)

Division of Hematology, Chaim Sheba Medical Center, Faculty of Medicine, Tel Aviv University, Tel Hashomer, Derech Sheba 2, 52621, Ramat Gan, Israel.

Jonathan Canaani (J)

Division of Hematology, Chaim Sheba Medical Center, Faculty of Medicine, Tel Aviv University, Tel Hashomer, Derech Sheba 2, 52621, Ramat Gan, Israel. Jonathan.Canaani@sheba.health.gov.il.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH